$375 Million is the total value of MPM BioImpact LLC's 32 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 62.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OLMA | Buy | Olema Pharmaceuticals, Inc. | $22,942,360 | +449.3% | 1,857,681 | +301.7% | 6.12% | +628.2% |
| GERN | Buy | Geron Corporation | $22,710,460 | -23.0% | 10,712,481 | +16.6% | 6.06% | +2.1% |
| IOVA | Buy | Iovance Biotherapeutics Inc | $14,957,656 | -28.0% | 3,287,397 | +11.4% | 3.99% | -4.5% |
| New | STRUCTURE THERAPEUTICS INC | $11,634,970 | – | 230,761 | +100.0% | 3.11% | – | |
| CBAY | New | CYMABAY THERAPEUTICS INC | $9,106,581 | – | 610,770 | +100.0% | 2.43% | – |
| FOLD | Buy | Amicus Therapeutics Inc. | $8,708,250 | +34.3% | 716,139 | +38.7% | 2.32% | +78.2% |
| Buy | Xeris Biopharma Holdings Inc | $7,417,619 | -28.8% | 3,987,967 | +0.3% | 1.98% | -5.6% | |
| AVDL | Buy | Avadel Pharmaceuticals PLC | $6,841,507 | +7.8% | 664,224 | +72.5% | 1.83% | +42.9% |
| MDGL | Buy | Madrigal Pharmaceuticals inc | $5,967,048 | -32.0% | 40,859 | +7.5% | 1.59% | -9.9% |
| MORF | New | MORPHIC HOLDING INC | $4,582,000 | – | 200,000 | +100.0% | 1.22% | – |
| PHAT | Buy | Phathom Pharmaceuticals inc | $3,601,833 | -10.9% | 347,332 | +23.0% | 0.96% | +18.2% |
| VKTX | New | VIKING THERAPEUTICS INC | $3,597,750 | – | 325,000 | +100.0% | 0.96% | – |
| New | Harpoon Therapeutics, Inc. | $1,288,270 | – | 319,670 | +100.0% | 0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.